Cadence’s HypertensionOS Software Enters FDA’s TEMPO Pilot for Chronic Care AI
Event summary
- Cadence’s HypertensionOS software selected as the second participant in FDA’s TEMPO pilot program on August 13, 2026.
- HypertensionOS is a prescription SaMD designed for clinician-supervised medication management of Stage 2 hypertension patients.
- Cadence treats over 100,000 active chronic disease patients across 20 leading health systems.
- Peer-reviewed research shows Cadence drives a 70% relative increase in blood-pressure control among hypertension patients.
The big picture
Cadence’s inclusion in the FDA’s TEMPO pilot marks a strategic validation of clinical AI’s role in chronic care automation. The program aligns with broader industry shifts toward technology-enabled patient outcomes, particularly as regulators seek to balance innovation with safety. With over 100,000 patients under management, Cadence is positioning itself as a key player in the future of scalable, AI-driven chronic disease treatment.
What we're watching
- Regulatory Pathway
- How the FDA’s TEMPO pilot will shape future regulatory frameworks for clinical AI in chronic care.
- Scalability Challenge
- Whether Cadence can sustain its 70% blood-pressure control improvement at national scale.
- Competitive Dynamics
- The pace at which other digital health companies enter the TEMPO program to validate their AI solutions.
Related topics